Giiant Pharma Inc., a Montreal, Canada based preclinical-stage biotech company, raised US$11M in seed funding.
The round was led by Amplitude Ventures and Genesys Capital, with participation from Fonds de solidarité FTQ, AmorChem II Fund, Theodorus Investment Funds, Anges Québec, and other angel investors.
The company intends to use the funds to initiate its IND-enabling preclinical program with its lead candidate, GT-2108, for the treatment of moderate-to-severe ulcerative colitis.
Led by Maxime Ranger, CEO, Dr. Elizabeth Kwong, Chief Development Officer, and Patrick Colin, Chief Clinical Officer, Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.